Article Details

POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of ...

Retrieved on: 2021-01-12 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of .... View article details on hiswai:

Excerpt

TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up